160 related articles for article (PubMed ID: 3291982)
1. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.
Greipp PR; Katzmann JA; O'Fallon WM; Kyle RA
Blood; 1988 Jul; 72(1):219-23. PubMed ID: 3291982
[TBL] [Abstract][Full Text] [Related]
2. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
Greipp PR; Lust JA; O'Fallon WM; Katzmann JA; Witzig TE; Kyle RA
Blood; 1993 Jun; 81(12):3382-7. PubMed ID: 8507875
[TBL] [Abstract][Full Text] [Related]
3. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin.
Schambeck CM; Bartl R; Höchtlen-Vollmar W; Wick M; Lamerz R; Fateh-Moghadam A
Am J Clin Pathol; 1996 Jul; 106(1):64-8. PubMed ID: 8701935
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma.
Witzig TE; Gertz MA; Lust JA; Kyle RA; O'Fallon WM; Greipp PR
Blood; 1996 Sep; 88(5):1780-7. PubMed ID: 8781435
[TBL] [Abstract][Full Text] [Related]
5. Serum beta 2-microglobulin at remission and relapse in patients with multiple myeloma.
Brenning G; Wibell L; Bergström R
Eur J Clin Invest; 1985 Oct; 15(5):242-7. PubMed ID: 3935453
[TBL] [Abstract][Full Text] [Related]
6. The Merlini, Waldenström, Jayakar staging system revisited.
Merlini G; Gobbi PG; Ascari E
Eur J Haematol Suppl; 1989; 51():105-10. PubMed ID: 2697581
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment serum beta 2-microglobulin in multiple myeloma.
Brenning G; Simonsson B; Källander C; Ahre A
Br J Haematol; 1986 Jan; 62(1):85-93. PubMed ID: 3510657
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma.
Scarffe JH; Anderson H; Palmer MK; Crowther D
Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1361-4. PubMed ID: 6357802
[TBL] [Abstract][Full Text] [Related]
9. A new staging system for multiple myeloma based on the number of S-phase plasma cells.
San Miguel JF; García-Sanz R; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
Blood; 1995 Jan; 85(2):448-55. PubMed ID: 7811998
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia.
Kantarjian HM; Smith T; Estey E; Polyzos A; O'Brien S; Pierce S; Beran M; Feldman E; Keating MJ
Am J Med; 1992 Dec; 93(6):599-604. PubMed ID: 1466355
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system.
Bataille R; Boccadoro M; Klein B; Durie B; Pileri A
Blood; 1992 Aug; 80(3):733-7. PubMed ID: 1638024
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study.
Durie BG; Stock-Novack D; Salmon SE; Finley P; Beckord J; Crowley J; Coltman CA
Blood; 1990 Feb; 75(4):823-30. PubMed ID: 2405920
[TBL] [Abstract][Full Text] [Related]
13. Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival.
Larsen JT; Chee CE; Lust JA; Greipp PR; Rajkumar SV
Blood; 2011 Sep; 118(10):2702-7. PubMed ID: 21750316
[TBL] [Abstract][Full Text] [Related]
14. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
15. [Serum ferritin and beta-2-microglobulin in multiple myeloma].
Linkesch W; Ludwig H
Acta Med Austriaca; 1982; 9(5-6):227-31. PubMed ID: 6187172
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in multiple myeloma.
Kyle RA
Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
[TBL] [Abstract][Full Text] [Related]
17. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group.
Pelliniemi TT; Irjala K; Mattila K; Pulkki K; Rajamäki A; Tienhaara A; Laakso M; Lahtinen R
Blood; 1995 Feb; 85(3):765-71. PubMed ID: 7530507
[TBL] [Abstract][Full Text] [Related]
18. Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies.
Boccadoro M; Durie BG; Frutiger Y; Gavarotti P; Redoglia V; Massaia M; D'Alberto M; Marmont F; Gallamini A; Tribalto M
Acta Haematol; 1987; 78(4):239-42. PubMed ID: 3122489
[TBL] [Abstract][Full Text] [Related]
19. Long-term prognostic value of serum beta 2 microglobulin in myelomatosis.
Cuzick J; De Stavola BL; Cooper EH; Chapman C; MacLennan IC
Br J Haematol; 1990 Aug; 75(4):506-10. PubMed ID: 2119793
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma.
Litam P; Swan F; Cabanillas F; Tucker SL; McLaughlin P; Hagemeister FB; Rodriguez MA; Velasquez WS
Ann Intern Med; 1991 May; 114(10):855-60. PubMed ID: 2014946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]